Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.46 |
| ▸ | RELA | Q04206 | 6/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634791 | 0.78 | MTNR1A (0.46) | DRD2 | |
| SCHEMBL173219 | 0.76 | EPHX2 (0.69) | EPHX2NFKB1NFKB2RELADRD2 | |
| SCHEMBL31694392 | 0.76 | EPHX2 (0.69) | EPHX2NFKB1NFKB2RELADRD2 | |
| SCHEMBL3375618 | 0.75 | PDE4A (0.52) | EPHX2DRD2KMT2A | |
| SCHEMBL57180 | 0.75 | MEN1 (0.52) | EPHX2KMT2ANAMPT | |
| SCHEMBL5432481 | 0.75 | MEN1 (0.52) | EPHX2KMT2ANAMPT | |
| SCHEMBL57241 | 0.75 | MEN1 (0.52) | EPHX2KMT2ANAMPT | |
| SCHEMBL56008 | 0.75 | MEN1 (0.52) | EPHX2KMT2ANAMPT | |
| SCHEMBL22787577 | 0.75 | MEN1 (0.52) | EPHX2KMT2ANAMPT | |
| SCHEMBL3375614 | 0.75 | PDE4A (0.52) | EPHX2DRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | EPHX2 3491/4885NFKB1 4093/4885NFKB2 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.